Regulatory news - Idogen

Regulatory news

1 April, 2020
Last day of trading with BTA in Idogen

31 March, 2020
Idogen receives MEUR 0.55 disbursement from Horizon 2020

30 March, 2020
Nomination Committee nominates cell therapy expert to Idogen AB’s Board of Directors

23 March, 2020
Idogen recruits a new Chief Medical Officer

18 March, 2020
Idogen publishes outcome in rights issue

28 February, 2020
Idogen publishes prospectus in connection with the forthcoming rights issue

17 February, 2020
Bulletin from the extraordinary general meeting in Idogen AB on February 17, 2020

7 February, 2020
Idogen presents at Biostock Live on February 13, 2020

5 February, 2020
Crown Princess and Prince Daniel visited Idogen

29 January, 2020
Idogen AB Year-end report 1 January-31 December 2019

28 January, 2020
Idogen AB (publ) announces rights issue of SEK 29 million

16 January, 2020
Idogen’s cell technology successfully advanced to large-scale production

13 December, 2019
Idogen files patent application for new tolerogenic cell therapy

13 November, 2019
Idogen signs collaboration agreement for the production of cell therapy in haemophilia

30 October, 2019
Idogen presents at Stora Aktiedagen in Gothenburg November 4th

22 October, 2019
Correction: Idogen AB Interim report January–September 2019

22 October, 2019
Idogen AB Interim report January–September 2019

23 September, 2019
Idogen’s investor events in October-November 2019

20 August, 2019
Interim report 1 January – 30 June 2019

15 July, 2019
Idogen appoints Anders Karlsson as new CEO

18 June, 2019
Idogen has successfully established a novel method for the company’s cell therapy

29 May, 2019
Idogen AB publishes Annual report for 2018

28 November, 2018
Idogen demonstrates proof-of-principle in a model of autoimmune disease

23 October, 2018
Interim report 1 January – 30 September 2018

18 October, 2018
Idogen’s investor events in October-November 2018

4 October, 2018
The Canadian Intellectual Property Office intends to grant Idogen’s patent application for tolerogenic cell therapy

26 September, 2018
Idogen’s IDO 8 granted orphan drug designation in the USA

21 August, 2018
Idogen AB Interim report January – June 2018

17 August, 2018
Idogen extends the project portfolio to projects in autoimmune diseases

25 April, 2018
Idogen appoints Hanne Risager Romedahl as new Chief Scientific Officer

24 April, 2018
Idogen AB Interim report January-March 2018

27 March, 2018
Idogen AB´s Annual report 2017 published

15 February, 2018
Year-end report 1 January – 31 December 2017

13 December, 2017
Idogen has been granted a patent in the USA for its immune therapy technology

13 September, 2017
BioStock publishes updated analysis of Idogen

21 June, 2017
Idogen participates in large Vinnova-initiative to make Sweden a leader in biological medicines

2 June, 2017
BioStock publishes analysis of Idogen

18 May, 2017
Idogen has been granted EUR 2.9 million funding from Horizon 2020

11 May, 2017
Tolerogenic vaccine for kidney transplantation to be next therapeutic area for Idogen

8 May, 2017
Nomination proposal strengthens Idogen’s Board within cell therapy and drug development

31 March, 2017
Idogen recruits Chief Medical Officer

23 March, 2017
European patent granted for Idogen’s vaccine technology

13 March, 2017
Idogen strengthens its position in the USA – important patent application receives Notice of Allowance

7 February, 2017
Idogen reaches formal granting of patent in Japan

16 January, 2017
Orphan drug designation formally granted for Idogen in Europe

13 January, 2017
The European Patent Office intends to grant Idogen’s patent application

12 December, 2016
Positive decision for Idogen’s orphan designation application in Europe

5 December, 2016
Japan Patent Office intends to grant Idogen’s patent application

30 November, 2016
Interview with Neil Thomas, Chief Business Officer in Idogen

21 November, 2016
Idogen signs agreement with global contract research partner

19 September, 2016
Idogen reports positive results for follow-up products in collaboration with the University of Oxford and strengthens the portfolio

12 September, 2016
Idogen reports important breakthrough – positive results from proof-of-concept study in human cells

8 July, 2016
Idogen initiates collaboration with the University of Oxford

8 July, 2016
Idogen reports positive pre-clinical results

Visit our news archive for older news

Idogen AB | Medicon Village | Scheelevägen 2 | SE-223 81 Lund | Sweden | E-mail: info at idogen dot com

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.